FindTrial
Sign In

A clinical trial to evaluate creatine kinase levels in newborns

Evaluation of muscle specific creatine kinase in newborns

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041821
Enrollment
5000
Registered
2022-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Department of Pediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive neonates born after 37 weeks of gestation with birth weight more than 2.5 kgs.

Exclusion criteria

Exclusion criteria: 1. Newborns who have received blood transfusion before collection of dried blood spot. 2. Newborns who have isolated congenital heart defects.

Design outcomes

Primary

MeasureTime frame
CK-MM levels in newborns as assessed by neonatal CK-MM kit.Timepoint: 1 month—

Secondary

MeasureTime frame
Prevalence of Duchenne Muscular Dystrophy in newborns with raised CK-MM levelsTimepoint: 1 year;Proportion of various causes responsible for raised neonatal CK-MM levelsTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Seema Kapoor

Maulana Azad Medical College and Associated Lok Nayak Hospital

drseemakapoor@gmail.com01123501512

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026